You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
17 Items
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Curative
Drugs Used:
DOXOrubicin,
bleomycin,
vinBLAStine,
dacarbazine
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2017
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    cobimetinib - For combination therapy (with vemurafenib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage III or IV melanoma
Exceptional Access Program
    vemURAFenib- For combination therapy (with cobimetinib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma
... Show more tags
Drugs Used:
cobimetinib,
vemURAFenib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Endocrine, Adrenal     
Intent: Palliative
Drugs Used:
cyclophosphamide,
vinCRIStine,
dacarbazine
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2017
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Drugs Used:
dacarbazine
... Show more tags
Quick Link(s):
Regimen Monograph
Jan 2017
Cancer Type: Gastrointestinal, Neuroendocrine (GI), Lung, Neuroendocrine (Lung)     
Intent: Palliative
Drugs Used:
dacarbazine,
EPIrubicin,
fluorouracil
... Show more tags
Quick Link(s):
Regimen Monograph
Dec 2017
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
... Show more tags
Drugs Used:
gefitinib
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Head and Neck     
Intent: Palliative
Drugs Used:
gefitinib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Interferon - Melanoma
... Show more tags
Drugs Used:
interferon alfa-2b
... Show more tags
Quick Link(s):
Regimen Monograph
Jan 2017
Cancer Type: Hematologic, Myeloproliferative Neoplasms (MPNs)     
Intent: Palliative
Drugs Used:
interferon alfa-2b
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2017
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Drugs Used:
interferon alfa-2b
... Show more tags
Quick Link(s):
Regimen Monograph
Dec 2017